Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled Virazole in Healthy Volunteers
NCT05229510Phase 1Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ribavirin in coronavirus disease 2019 (COVID-19) and respiratory syncytial virus infection (RSV) (5 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Percentage of participants with treatment-emergent adverse events at 40 days. Started Mar 2021; status: completed.
02
Drugs
ribavirin
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05229510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229510.